Responsible and loving pet owners must have a first aid kit with a set of various products and medications that may be needed to help their pet. Properly selected drugs in the kit help not only alleviate the animal’s condition, but also often save its life. The drug “Etamzilat” for cats and dogs is one of those emergency medications that are used to stabilize the pet’s condition until the veterinarian arrives.
“Etamzilat” for cats and dogs is exactly one of those emergency aids that it is advisable to have in the first aid kit
Nosological classification (ICD-10)
- D65-D69 Bleeding disorders, purpura and other hemorrhagic conditions
- I78.8 Other diseases of capillaries
- K92.2 Gastrointestinal bleeding, unspecified
- N92 Heavy, frequent and irregular menstruation
- N93 Other abnormal bleeding from the uterus and vagina
- R04.8.0* Pulmonary hemorrhage
- R58 Bleeding, not elsewhere classified
- T81.0 Bleeding and hematoma complicating the procedure, not elsewhere classified
When to use the drug
The drug is used as a first-aid substance for injuries that provoke heavy bleeding. It is also acceptable to use to prevent internal bleeding, but only on the recommendation of a veterinarian. Etamsylate cannot be used as a drug for long-term therapy. Etamsylate is prescribed to animals after surgery and other invasive medical procedures to reduce the risk of internal bleeding. Bitches - during childbirth. It is also prescribed for injuries to internal organs or existing bleeding.
"Etamzilat" is prescribed to animals after surgery.
The drug is prescribed after heart attacks and strokes, for thrombocytopathy and hemorrhagic syndrome. At home, it is used to combat bleeding if the animal has received injuries accompanied by heavy blood loss.
Directions for use and doses
IV, IM 1 hour before surgery, for prophylaxis - 0.25–0.5 g (2–4 ml of 12.5% solution). If there is a risk of postoperative bleeding - 0.5–0.75 g (4–6 ml) per day. If necessary, 0.25–0.5 g (2–4 ml) is administered intravenously during surgery. For medicinal purposes - 0.25-0.5 g (2-4 ml) at a time, and then - 0.25 g every 4-6 hours. Can be administered intravenously, adding to regular infusion solutions. For metro and menorrhagia - 0.25 g every 6 hours for 5-10 days, then - 0.25 g 2 times a day during hemorrhage. For hemorrhagic diathesis and diabetic microangiopathies - 0.25–0.5 g 1–2 times a day.
Etamzilat tablets 250 mg No. 10x5
Name
Etamzilat tablet 250 mg in container pack No. 10x5
Description
The tablets are round, flat on both sides, scored and chamfered, white or almost white, marbling is allowed. The score is not intended to divide the tablet into two equal doses.
Release form
pills
Dosage
250 mg
Pharmacological properties
Pharmacodynamics
Etamsylate is a synthetic hemostatic and angioprotective agent that acts at the initial stage of hemostasis (at the stage of interaction between the endothelium and platelets). By improving platelet adhesion and restoring capillary resistance, it reduces the duration of bleeding and the amount of blood loss. Suppresses the breakdown of mucopolysaccharides of the vascular wall, thus increasing the resistance of capillaries, reducing the permeability and fragility of microvessels. The drug does not have a vasoconstrictor effect and does not affect fibrinolysis and plasma coagulation factors.
Pharmacokinetics
When taken orally, etamsylate is slowly and completely absorbed from the gastrointestinal tract. Absolute bioavailability has not been established. After taking 500 mg orally, the maximum plasma concentration of 15 mcg/ml is achieved after approximately 4 hours. It is evenly distributed in various organs and tissues (depending on the degree of their blood supply). Plasma protein binding is about 95%. Penetrates through the placental barrier. Similar drug levels are observed in maternal and cord blood. There is no data on the penetration of ethamsylate into breast milk. Etamsylate is metabolized only to a limited extent. The plasma half-life averages 3.7 hours. About 72% of the dose is excreted unchanged in the urine during the first 24 hours. Whether the pharmacokinetics of etamsylate changes in patients with renal and/or hepatic impairment is unknown. Information on the pharmacokinetics of the drug in pediatric patients and elderly patients is not available.
Indications for use
In surgery Prevention and treatment of pre- and postoperative capillary bleeding during all complex operations or operations on well-vascularized organs and tissues in otorhinolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology, plastic and reconstructive surgery. In therapy Prevention and treatment of capillary bleeding of any origin and location: hematuria, intestinal bleeding, hematemesis, melena, nosebleeds, bleeding from the gums. In gynecology Metrorrhagia, primary menorrhagia or menorrhagia caused by an intrauterine contraceptive device, in the absence of organic pathology.
Directions for use and doses
Take orally, during or after meals, without chewing. Adults and adolescents (over 14 years of age) Preoperatively: 1–2 tablets (250–500 mg) one hour before surgery. After surgery: 1-2 tablets (250-500 mg) every 4-6 hours for as long as there is a risk of bleeding. In therapy: 2 tablets (500 mg) 2-3 times a day (1000-1500 mg) with meals, with a small amount of liquid. In gynecology for menopause and metrorrhagia: 2 tablets (500 mg) 3 times a day (1500 mg) with meals, with a small amount of liquid. Treatment begins 5 days before the expected start of monthly bleeding and continues for 10 days. Children under 14 years of age Half the adult dose (i.e., no more than 3 tablets per day, taken in three divided doses). Use of this drug in tablet form is not recommended in children younger than 6 years of age because they may have difficulty swallowing or in older children and adults who have difficulty swallowing tablets. Patients with hepatic or renal impairment No clinical trials have been conducted in patients with hepatic or renal impairment. Therefore, caution must be exercised when prescribing to such patients. Elderly patients Due to the likelihood of a decrease in renal and hepatic functions in old age, the functioning of these organs should be monitored during treatment. If you miss a dose, take the usual dose as soon as you remember. Do not take the missed dose until it is almost time for your next dose. Never double the dose to make up for a missed dose.
Use during pregnancy and lactation
There are limited data on the use of ethamsylate in pregnant women. Animal studies showed no direct or indirect reproductive toxicity. Etamsylate crosses the placenta; concentrations of etamsylate in maternal and cord blood are comparable. As a precaution, ethamsylate should not be used during pregnancy unless absolutely necessary. Due to the lack of data on the ability of ethamsylate to pass into breast milk, breastfeeding is not recommended during maternal treatment. If breastfeeding continues, you need to stop taking the medicine.
Precautionary measures
Patients taking etamsylate should be under medical supervision. Monitoring also implies the possibility of a need to study hemostasis parameters. Before starting treatment, other causes of bleeding should be excluded. If a drug is prescribed to reduce excessively heavy and/or prolonged menstrual bleeding and the desired effect cannot be achieved, it is necessary to exclude the presence of another pathology that can cause such conditions. Cases of isolated fever that recurs when etamsylate is re-administered have been reported. If fever occurs, treatment with etamsylate should be discontinued and not restarted. Caution should be exercised when prescribing to patients with a history of thrombosis or thromboembolism, bleeding due to an overdose of anticoagulants, in patients with renal failure. After the use of ethamsylate, the use of high molecular weight plasma substitutes is possible. There is evidence of the ineffectiveness of etamsylate in patients with thrombocytopenia.
Interaction with other drugs
To date, no drug interactions or incompatibility with other drugs have been identified. Combination with aminocaproic acid and vikasol is acceptable. If laboratory monitoring (for example, blood tests) is necessary during treatment, it should be carried out before the first daily dose of the drug, in order to exclude the influence of ethamsylate during laboratory tests.
Contraindications
- hypersensitivity to ethamsylate or any of the excipients (including galactose intolerance, lactase deficiency or glucose-galactose malabsorption);
- acute porphyria;
- increased blood clotting, thrombosis, thromboembolism;
- hemoblastosis in children (lymphatic and myeloid leukemia, osteosarcoma);
- children up to 6 years of age (for this form of release).
Compound
one tablet contains: active ingredient – etamsylate – 250 mg; excipients: citric acid monohydrate, povidone, corn starch, magnesium stearate, lactose monohydrate.
Overdose
There are no data on overdose. Treatment: symptomatic.
Side effect
Adverse reactions are listed according to the classification of undesirable side effects in accordance with the damage to organs and organ systems and the frequency of development: very common (? 1/10), frequent (? 1/100 to
Storage conditions
In a place protected from light and moisture, at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Contraindications
Attention! Etamsylate is used with extreme caution and only under the supervision of a physician for animals that have previously had thrombosis or have recently been treated with anticoagulants. If your pet has an allergic reaction to lactose or glucose, the drug should not be used.
The use of Etamzilate in old and weakened animals, and in pets with chronic kidney and liver pathologies is also prohibited. No negative effects were observed when administering Etamsylate to pregnant animals, but it should be used with extreme caution if the doctor determines that the benefits of the drug are incomparably higher than the possible risks.
Brief information about liver diseases in cats
Possible side effects
As a rule, animals tolerate the drug very well. Exceptions may occur in the presence of individual rejection of the main active ingredient or additional components.
Animals usually tolerate the drug well
Side effects may include:
- nausea;
- dizziness;
- violation of orientation in space;
- vomit;
- stomach pain;
- redness on the mucous membranes;
- change in skin color, rash.
Undesirable effects occur quite rarely and are not the norm. If any side effect occurs, you must immediately visit a veterinarian and discuss the possibility of replacing the drug with another one of a similar effect.
